



# **INTEGRATED PROTEINS LIMITED**

**City Point, 5<sup>th</sup> Floor, Opp. Town Hall, Jamnagar – 361 001, Gujarat, India**

Phone: (0288) 2551901 Fax: (0288) 2552566

Email ID: [ipl.complianceofficer@gmail.com](mailto:ipl.complianceofficer@gmail.com)

Website: [www.integratedproteins.com](http://www.integratedproteins.com) CIN:

L15400GJ1992PLC018426

**Ref: IPL/BSE/Financial Results**

**Date: 11<sup>th</sup> August, 2023**

To,  
**Department of Corporate Service**  
BSE Limited  
Phiroz Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001

**Sub: Financial Results**

**Ref : Scrip Code - 519606**

**Respected Sir / Madam,**

Further to our letter dated 5<sup>th</sup> August, 2023 and with reference to captioned subject, kindly be informed that the Board at its meeting held today ; i.e 11<sup>th</sup> August, 2023 has interalia considered and approved the unaudited financial results for the quarter ended 30<sup>th</sup> June, 2023

The unaudited financial results along with the Limited Review Report from our Statutory Auditor M/s DGMS and Co, Chartered Accountants is enclosed herewith.

You are requested to take above on your records.

Thanking you in anticipation.

**FOR, INTEGRATED PROTEINS LIMITED**

**CS Devanshi V. Shah(A50711)**  
**Company Secretary and Compliance Officer**



# INTEGRATED PROTEINS LIMITED

CIN: L15400GJ1992PLC018426

Registered Office: CITY POINT, OPP- TOWN HALL JAMANAGAR Jammagar GJ 361008 IN

## Unaudited Standalone Statement of Financial Results for the Quarter Ended 30-06-2023

(Rs. In Lakh except per share data)


Particulars	Quarter Ended			Year Ended
	30-06-2023	31-03-2023	30-06-2022	31-03-2023
A	Date of start of reporting period	01-04-2023	01-01-2023	01-04-2022
B	Date of end of reporting period	30-06-2023	31-03-2023	30-06-2022
C	Whether results are audited or unaudited	Unaudited	Audited	Unaudited
<b>Part I</b>				
<b>I</b>	<b>Revenue From Operations</b>			
	Net sales or Revenue from Operations	-	16.70	-
				16.70
<b>II</b>	<b>Other Income</b>	3.92	3.96	3.88
				15.61
<b>III</b>	<b>Total Income (I + II)</b>	3.92	20.66	3.88
				32.31
<b>IV</b>	<b>Expenses</b>			
(a)	Cost of materials consumed	-	-	-
(b)	Purchases of stock-in-trade	-	14.70	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-
(d)	Employee benefit expense	0.54	0.28	0.54
(e)	Finance Costs	-	-	-
(f)	Depreciation and amortisation expense	0.72	(0.81)	0.72
(g)	Other Expenses	4.19	1.72	3.73
				10.25
	<b>Total expenses</b>	5.45	15.89	4.99
				28.13
<b>V</b>	<b>Profit (loss) before Exceptional and Extraordinary Items and tax (III-IV)</b>	(1.53)	4.77	(1.11)
<b>VI</b>	<b>Exceptional items</b>			
<b>VIII</b>	<b>Profit (loss) before Tax (V-VI)</b>	(1.53)	4.77	(1.11)
<b>X</b>	<b>Tax Expense</b>			
(a)	Current Tax	(0.40)	1.85	0.19
	(Less):- MAT Credit	-	-	-
	Current Tax Expense Relating to Prior years	-	-	-
(b)	Deferred Tax (Asset)/Liabilities	1.53	(0.60)	(0.13)
<b>XI</b>	<b>Net Profit/Loss for the period from Continuing Operations (IX-X)</b>	(2.66)	3.52	(1.17)
<b>XII</b>	<b>Profit (Loss) from Discontinuing Operations</b>	-	-	-
<b>XIII</b>	<b>Tax Expenses of Discontinuing Operations</b>	-	-	-
<b>XIV</b>	<b>Net Profit (Loss) from Discontinuing Operations after tax (XII-XIII)</b>	-	-	-
<b>XV</b>	<b>Profit (Loss) for the period (XI+XIV)</b>	(2.66)	3.52	(1.17)
<b>XVI</b>	<b>Other Comprehensive Income</b>			
	a. i). Amount of item that will not be reclassified to profit or loss	-	-	-
	ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-
	b i). Item that will be reclassified to profit or loss	-	-	-
	ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-
<b>XVII</b>	<b>Total Comprehensive income</b>	0.00	0.00	0.00
	<b>Total Comprehensive income [Comprising Profit for the Period (After tax) and Other comprehensive income] (XV+XVII)</b>	(2.66)	3.52	(1.17)
<b>XVIII</b>	<b>Details of equity share capital</b>			
	Paid-up equity share capital (Face Value of Rs. 10/- per equity share)	352.02	352.02	352.02
	Face value of equity share capital (Per Share)	Rs. 10/-	Rs. 10/-	Rs. 10/-
	Other Equity			
<b>XIX</b>	<b>Earnings per share (Not Annualized for Year ended)</b>	(0.08)	0.10	(0.03)
(a)	<b>Earnings per share Continuing Operation ( Not Annualised for Year ended )</b>			
	Basic earnings per share before extraordinary items	(0.08)	0.10	(0.03)
	Diluted earnings per share before extraordinary items	(0.08)	0.10	(0.03)
(b)	<b>Earnings per share Discontinuing Operation ( Not Annualised for Year ended )</b>			
	Basic earnings per share after extraordinary items	0.00	0.00	0.00
	Diluted earnings per share after extraordinary items	0.00	0.00	0.00
(c)	<b>Earnings per share ( Not Annualised for Year ended )</b>			
	Basic earnings per share before extraordinary items	(0.08)	0.10	(0.03)
	Diluted earnings per share before extraordinary items	(0.08)	0.10	(0.03)

**Notes:-**

**Notes to Unaudited Standalone financials results for the year ended 30th June 2023:**

- 1 The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards Amendment Rules 2016.
- 2 The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.
- 3 The Audit Committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 11th August, 2023.
- 4 The Company has single reportable business segment. Hence, no separate information for segment wise disclosure is given in accordance with the requirements of Indian Accounting Standard (Ind AS) 108 - "Operating Segments".

Date :- 11th August, 2023  
Place :- Jammagar



FOR, INTEGRATED PROTEINS LIMITED

**CHINTAN ARVIND SHAH**  
 MANAGING DIRECTOR  
 DIN: 00228733





**Independent Auditor's Review Report on Quarterly Unaudited Standalone Financial Results of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (as amended)**

**To The Board of Directors of  
Integrated Proteins Limited**

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Integrated Proteins Limited** ("the Company") for the quarter ended 30<sup>th</sup> June 2023 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors at their meeting held on **11<sup>th</sup> August 2023**, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standards 34 "Interim Financial Reporting" (Ind AS 34), as prescribed under section 133 of the Companies Act, 2013 as amended, read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review of the Statement conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For D G M S & Co.  
Chartered Accountants

Shashank P. Doshi  
Partner

Membership No. 108456

Firm Regn. No. 0112187W

UDIN: 23108456BGUDQK4172

Date: 11<sup>th</sup> August 2023

Place: Jamnagar

**Head Office :** 217/218/219, Manek Center, P.N. Marg, Jamnagar - 361008.

**Branch Office :** B-15/16, 5th Floor, B Wing, Shree Siddhivinayak Plaza, Veera Desai Industrial Estate, Next to T Series Business Park, Andheri West, Mumbai - 400 053.

**Cell:** +91 98242 31214 **Ph.:** 0288 2661942 **Email:** dgmsco.jam@gmail.com